IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merial Limited v Novartis AG [2014] APO 19
Patent Application: 2010206029
Title:Palatable ductile chewable veterinary composition
Patent Applicant: Novartis AG
Opponent: Merial Limited
Delegate: Dr S.D.Barker
Decision Date: 1 April 2014
Hearing Date: Written submissions filed on 4 March 2014
Catchwords: PATENTS – Further evidence – reg 5.10(4) – nature and significance of evidence supports further evidence – further evidence allowed.
Representation: Patent applicant: Davies Collison Cave
Opponent:FB Rice
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2010206029
Title:Palatable ductile chewable veterinary composition
Patent Applicant: Novartis AG
Date of Decision: 1 April 2014
DECISION
I allow the further evidence.
I allow Merial Limited two (2) months from the date of this decision to file any evidence responding to the further evidence.
I award costs against Merial Limited.
REASONS FOR DECISION
Background
Patent application 2010206029 (the application) is a divisional of 2008201605 (the parent). The parent is itself a divisional application which was opposed and then withdrawn on 2 April 2013.
The application was filed by Novartis AG (Novartis) on 29 July 2010. It was advertised as accepted on 9 August 2012. A notice of opposition to the grant of a patent was filed by Merial Limited (Merial) on 9 November 2012. The statement of grounds and particulars was served and filed on 31 January 2013. The evidence in support was completed on 27 April 2013.
The evidentiary period to file evidence in answer therefore started on 27 April 2013 so the evidence in answer was due on 29 July 2013. This period was extended to 29 October 2013.
Evidence in answer, in the form of a first declaration by from Dr Rowe was filed on 22 July 2013 and his 2nd, 3rd and 4th declarations were filed on 24 October 2013.
On 29 October 2013 Novartis filed another request for an extension of time to file more evidence in answer. This extension of time was opposed and a hearing was held on 25 November 2013. On 27 November Dr Rowe’s 5th and 6th declarations were filed.
On 5 December 2013 a Deputy Commissioner refused the extension of time, see Merial Limited v Novartis AG [2013] APO 65. The consequence of this decision is that Dr Rowe’s 5th and 6th declarations do not make up any part of the evidence in answer.
On 13 January 2014 Novartis sought leave to file Dr Rowe’s 5th and 6th declarations as further evidence under regulation 5.10(4). Merial opposed that application. The parties were heard on the basis of written submissions.
The Law
On 15 April 2013, the Intellectual Property Legislation Amendment (Raising the Bar) Regulation 2013 (No 1) (the Amendment Regulation) commenced. The Amendment Regulation significantly amended the Patents Regulations (the Regulations) as they apply to patent oppositions. Pursuant to subregulation 23.36, item 2, an application to file further evidence in this opposition is governed by subregulations 5.10(4) and 5.10(5) as…
Keep reading for free
Create a free CaseChat account to read Merial Limited v Novartis AG and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2014] APO 19
- Decision Date
CaseChat Overview and Summary
The key legal issues that the court had to address were whether the delegate had the authority to permit the filing of further evidence and, if so, under what circumstances such evidence could be admitted. The court also needed to determine whether the evidence proposed by Novartis AG was significant and relevant enough to warrant an extension of the evidence submission period. Furthermore, the court had to consider the impact of the delay in submitting the evidence and whether any prejudice caused to Merial Limited by this delay would be a factor in its decision.
The court found that, under the relevant regulations, the delegate did have the authority to permit the filing of further evidence if it was deemed appropriate in all the circumstances. The court emphasised that the decision to allow further evidence should not be constrained by a rigid requirement for a satisfactory explanation of the delay. Instead, the focus should be on the nature and significance of the evidence itself. In this case, the evidence proposed by Novartis AG, which included expert opinions on the documents raised as evidence in support, was considered to be of a kind that was likely to be significant to the case. While the delay in submitting the evidence was not fully explained to the court's satisfaction, the nature and significance of the evidence outweighed this issue. Consequently, the court allowed the further evidence and granted Merial Limited two months to file any evidence in response. The court also awarded costs against Merial Limited.
In summary, the court allowed the further evidence to be submitted by Novartis AG, granted Merial Limited two months to file any responding evidence, and awarded costs against Merial Limited. This decision highlights the importance of considering both the nature and significance of the evidence, as well as the impact of any delay in submitting such evidence, when determining whether to permit the filing of further evidence in patent opposition proceedings.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.